The CANDLE study met its primary endpoint, with 65.4% of patients with recurrent vulvovaginal candidiasis (RVCC) who received monthly single-day...
Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourth quarterCONSHOHOCKEN, Pa.,...
– CFT7455, a Novel IKZF1/3 Degrader, Advancing Through Dose Escalation Portion of Phase 1/2 Clinical Trial – – Phase 1/2 Clinical...
Study evaluating the safety and efficacy of gemlapodect (NOE-105) in adults with Childhood Onset Fluency Disorder (also known as stuttering)Top-line...
– MGTA-117 Phase 1/2 clinical trial progress continues and remains consistent with earlier observations of target binding, target cell reductions,...
Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse eventsFLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE...
The combination of data and analytics will accelerate pharmaceutical breakthroughs by helping clinical trial teams uncover the best sites and...
Single ascending dose (SAD) Phase 1 Study completed in Australia with a maximum dose of 2,000 mg.Pharmacokinetics (PK) were dose...
BergaMet PRO+ Citrus Bergamot SuperFruit™ BergaMet PRO+ Citrus Bergamot SuperFruit™LAS VEGAS, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Healthy Extracts Inc....
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile...
Nes-Ziona, Israel, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ETSAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Capricor...
ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution...
Company to host conference call to discuss financial results and provide a corporate update on August 9, 2022 at 4:30...
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that...
GreenLight Woburn lab 2 GreenLight’s messenger RNA production process is transferable to large-scale equipment and CMO facilitiesGreenLight’s messenger RNA production...
ProLectin-M, a new class of oral antiviral drug BOSTON, MASSACHUSETTS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (Symbol: BIXT)...
HAMILTON, BERMUDA , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Enrollment to be continued to 160 subjects, adding 24 to ensure...
Submission has been granted priority review and given a target regulatory decision date of November 30, 2022.If approved for this...